TRI-LO-ESTARYLLA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tri-lo-estarylla, and when can generic versions of Tri-lo-estarylla launch?
Tri-lo-estarylla is a drug marketed by Xiromed and is included in one NDA.
The generic ingredient in TRI-LO-ESTARYLLA is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
Summary for TRI-LO-ESTARYLLA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 6 |
Patent Applications: | 8 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRI-LO-ESTARYLLA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TRI-LO-ESTARYLLA
US Patents and Regulatory Information for TRI-LO-ESTARYLLA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xiromed | TRI-LO-ESTARYLLA | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 091232-001 | Jun 29, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |